Shopping Cart
- Remove All
Your shopping cart is currently empty
Tremelimumab
Catalog No. T77466Cas No. 745013-59-6
Alias Ticilimumab, CP-675206
Tremelimumab is a cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blocking antibody.Tremelimumab is often used in combination with Durvalumab for the treatment of solid cancers such as hepatocellular carcinoma and lung cancer.
Tremelimumab
Catalog No. T77466Alias Ticilimumab, CP-675206Cas No. 745013-59-6
Tremelimumab is a cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blocking antibody.Tremelimumab is often used in combination with Durvalumab for the treatment of solid cancers such as hepatocellular carcinoma and lung cancer.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $155 | In Stock | |
| 5 mg | $472 | In Stock | |
| 10 mg | $690 | In Stock | |
| 25 mg | $1,080 | In Stock | |
| 50 mg | $1,460 | In Stock | |
| 100 mg | $1,970 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreSelect Batch
Concentration:4.64 mg/mL
Purity:98.7% (SEC-HPLC)
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | Tremelimumab is a cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blocking antibody.Tremelimumab is often used in combination with Durvalumab for the treatment of solid cancers such as hepatocellular carcinoma and lung cancer. |
| In vitro | Tremelimumab exhibits a higher binding affinity for CTLA-4-Ig compared to CD28-Ig, demonstrating specificity for cynomolgus monkeys and humans. It does not engage with human leukocyte FcγR, mitigating the risk of cytokine release syndrome. Interestingly, Tremelimumab enhances IL-2 production in a concentration-dependent manner when stimulated with staphylococcal enterotoxin A, showcasing its ability to modulate T-cell responses.[1] |
| Alias | Ticilimumab, CP-675206 |
| Molecular Weight | 146.3 kDa |
| Cas No. | 745013-59-6 |
Storage & Solubility Information
| Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Tremelimumab | purchase Tremelimumab | Tremelimumab cost | order Tremelimumab | Tremelimumab chemical structure | Tremelimumab in vitro | Tremelimumab molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.